EyePoint (EYPT) Other Non-Current Liabilities (2011 - 2026)
EyePoint (EYPT) posted Other Non-Current Liabilities of $55000.0 for Q1 2026, down 36.78% sequentially from $87000.0 in Q4 2025, and down 68.93% YoY from $177000.0 in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
EyePoint has reported Other Non-Current Liabilities for 11 years, with the latest figure at $55000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 68.93% year-over-year to $55000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55000.0 (down 68.93% YoY) and the FY2025 annual result came in at $87000.0, down 57.56% from the prior year.
- Other Non-Current Liabilities slipped to $55000.0 in Q1 2026 per EYPT's latest filing, from $87000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $658000.0 in Q1 2022 and troughed at $100.0 in Q2 2024.
- A 5-year average of $298650.0 and a median of $191000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 83.33% in 2024, then soared 147900.0% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $600000.0 in 2022, then changed by 0.0% to $600000.0 in 2023, then slumped by 65.83% to $205000.0 in 2024, then tumbled by 57.56% to $87000.0 in 2025, then plunged by 36.78% to $55000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $55000.0, $87000.0, and $118000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Sep 30, 2025 | 118,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Sep 30, 2024 | 233,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2023 | 600,000.00 |
| Dec 31, 2022 | 600,000.00 |
| Sep 30, 2022 | 600,000.00 |
| Jun 30, 2022 | 600,000.00 |
| Mar 31, 2022 | 658,000.00 |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 2.36 Mn |
| Jun 30, 2021 | 2.33 Mn |
| Mar 31, 2021 | 2.35 Mn |
| Dec 31, 2020 | 2.37 Mn |